Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Jul;59(7):2279–2284. doi: 10.1128/iai.59.7.2279-2284.1991

Characterization and immunogenicity of EX880, a Salmonella typhi Ty21a-based clone which produces Vibrio cholerae O antigen.

S R Attridge 1, C Dearlove 1, L Beyer 1, L van den Bosch 1, A Howles 1, J Hackett 1, R Morona 1, J LaBrooy 1, D Rowley 1
PMCID: PMC258007  PMID: 1711014

Abstract

EX645 is a derivative of Salmonella typhi Ty21a which carries a plasmid specifying production of Vibrio cholerae O antigen. When cultured with exogenous galactose to overcome the galE defect of the vector, EX645 also synthesizes S. typhi O antigen, and this can result in the masking of the shorter V. cholerae O antigen on the bacterial surface. To determine whether the potential for such masking at least partly underlies the inconsistency of anti-V. cholerae responses elicited by EX645, a derivative of this strain has been isolated, characterized, and tested for immunogenicity in human volunteers. EX880 has an rfb defect which prevents synthesis of S. typhi O antigen, and consequently V. cholerae O antigen is still detectable on the surface of the clone following growth in the presence of galactose. Compared with EX645, EX880 more consistently elicited significant rises in serum bactericidal antibody levels, although individual responses within a cohort still varied widely.

Full text

PDF
2279

Images in this article

2281Image
on p.2281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Attridge S. R., Daniels D., Morona J. K., Morona R. Surface co-expression of Vibrio cholerae and Salmonella typhi O-antigens on Ty21a clone EX210. Microb Pathog. 1990 Mar;8(3):177–188. doi: 10.1016/0882-4010(90)90045-r. [DOI] [PubMed] [Google Scholar]
  2. Black R. E., Levine M. M., Clements M. L., Young C. R., Svennerholm A. M., Holmgren J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun. 1987 May;55(5):1116–1120. doi: 10.1128/iai.55.5.1116-1120.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Collins L. V., Attridge S., Hackett J. Mutations at rfc or pmi attenuate Salmonella typhimurium virulence for mice. Infect Immun. 1991 Mar;59(3):1079–1085. doi: 10.1128/iai.59.3.1079-1085.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Forrest B. D. Identification of an intestinal immune response using peripheral blood lymphocytes. Lancet. 1988 Jan 16;1(8577):81–83. doi: 10.1016/s0140-6736(88)90284-x. [DOI] [PubMed] [Google Scholar]
  5. Forrest B. D. The development of a bivalent vaccine against diarrhoeal disease. Southeast Asian J Trop Med Public Health. 1988 Sep;19(3):449–457. [PubMed] [Google Scholar]
  6. Germanier R., Fürer E. Characteristics of the attenuated oral vaccine strain "S. typhi" Ty 21a. Dev Biol Stand. 1983;53:3–7. [PubMed] [Google Scholar]
  7. Gilman R. H., Hornick R. B., Woodard W. E., DuPont H. L., Snyder M. J., Levine M. M., Libonati J. P. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis. 1977 Dec;136(6):717–723. doi: 10.1093/infdis/136.6.717. [DOI] [PubMed] [Google Scholar]
  8. Hone D. M., Attridge S. R., Forrest B., Morona R., Daniels D., LaBrooy J. T., Bartholomeusz R. C., Shearman D. J., Hackett J. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun. 1988 May;56(5):1326–1333. doi: 10.1128/iai.56.5.1326-1333.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Levine M. M., Ferreccio C., Black R. E., Tacket C. O., Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis. 1989 May-Jun;11 (Suppl 3):S552–S567. doi: 10.1093/clinids/11.supplement_3.s552. [DOI] [PubMed] [Google Scholar]
  10. Levine M. M., Kaper J. B., Herrington D., Losonsky G., Morris J. G., Clements M. L., Black R. E., Tall B., Hall R. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun. 1988 Jan;56(1):161–167. doi: 10.1128/iai.56.1.161-167.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Manning P. A., Beutin L., Achtman M. Outer membrane of Escherichia coli: properties of the F sex factor traT protein which is involved in surface exclusion. J Bacteriol. 1980 Apr;142(1):285–294. doi: 10.1128/jb.142.1.285-294.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Migasena S., Pitisuttitham P., Prayurahong B., Suntharasamai P., Supanaranond W., Desakorn V., Vongsthongsri U., Tall B., Ketley J., Losonsky G. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun. 1989 Nov;57(11):3261–3264. doi: 10.1128/iai.57.11.3261-3264.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mosley W. H., McCormack W. M., Ahmed A., Chowdhury A. K., Barui R. K. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull World Health Organ. 1969;40(2):187–197. [PMC free article] [PubMed] [Google Scholar]
  14. Nevola J. J., Stocker B. A., Laux D. C., Cohen P. S. Colonization of the mouse intestine by an avirulent Salmonella typhimurium strain and its lipopolysaccharide-defective mutants. Infect Immun. 1985 Oct;50(1):152–159. doi: 10.1128/iai.50.1.152-159.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tacket C. O., Forrest B., Morona R., Attridge S. R., LaBrooy J., Tall B. D., Reymann M., Rowley D., Levine M. M. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun. 1990 Jun;58(6):1620–1627. doi: 10.1128/iai.58.6.1620-1627.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tagliabue A., Villa L., De Magistris M. T., Romano M., Silvestri S., Boraschi D., Nencioni L. IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. J Immunol. 1986 Sep 1;137(5):1504–1510. [PubMed] [Google Scholar]
  17. Wilkinson R. G., Gemski P., Jr, Stocker B. A. Non-smooth mutants of Salmonella typhimurium: differentiation by phage sensitivity and genetic mapping. J Gen Microbiol. 1972 May;70(3):527–554. doi: 10.1099/00221287-70-3-527. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES